PBS Biotech has appointed Martin Simonetti as Chief Executive Officer (CEO) as of October 27th, 2025. Simonetti is a veteran biotech executive who brings more than 40 years' industry expertise and leadership to PBS Biotech, including C-suite leadership, public and private financing and executing large-scale pharmaceutical collaborations. As part of the company's leadership evolution, PBS founder Dr Brian Lee will assume the role of Chief Technology Officer (CTO) and lead technology strategy and product innovation while continuing to serve as Chairman of the Board.

"I'm thrilled to welcome Marty as CEO of PBS Biotech. He brings the strategic insight and operational leadership needed to guide PBS through its next phase of growth. Marty is the right leader to drive our expansion and position PBS as the go-to partner for cell and gene therapy companies transforming patient treatment,” said Dr Brian Lee, Founder, CTO, and Chairman of the Board.

Simonetti has led growth and transformation across emerging biotech ventures and global lifesciences companies. He previously served as President and CEO at VLST Corporation and as Chief Financial Officer (CFO), Senior Vice President of Finance, and Treasurer at Dendreon Corporation.

Earlier in his career, he held leadership roles at Amgen, where he served as Vice President of Operations and Finance for Amgen BioPharma and Director of Colorado Operations.

Prior to Amgen, Simonetti worked in research and finance at Genentech, Inc. He currently serves on the Board of Directors of Curtana Pharmaceuticals and Eisana Corp. He earned an MS from the University of California, Davis, and an MBA from Santa Clara University.

"PBS Biotech is a proven innovator in bioreactor technology as well as biomanufacturing processes and is poised to expand its leadership in the cell therapy market. Having served on the PBS Advisory Board for nearly a decade, I'm honoured to step into this role and work with Brian and the team to scale our impact as demand for advanced bioprocessing solutions accelerates. Together, we'll help our customers translate breakthrough science into real-world treatments that improve patients' lives," said Simonetti.